<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-11-30" updated="2019-12-02">
  <drugbank-id primary="true">DB09563</drugbank-id>
  <name>Choline C-11</name>
  <description>Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging.</description>
  <cas-number/>
  <unii>M4AS4XGD4Q</unii>
  <average-mass>103.173</average-mass>
  <monoisotopic-mass>103.118424313</monoisotopic-mass>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links>
      <link>
        <ref-id>L660</ref-id>
        <title>FDA label</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203155s000lbl.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Choline C 11 Injection is indicated for  positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT)    or magnetic resonance imaging (MRI).  In these patients, 11 C-choline PET  imaging may  help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.  In clinical studies, imag   es w  ere produced with PET/CT coregistration. </indication>
  <pharmacodynamics>In a study of men with prostatic hyperplasia or primary prostate cancer, PET imaging showed 11C-choline radioactivity accumulated rapidly within the prostate; uptake appeared to peak by five minutes following injection of the drug and activity was retained over the subsequent 30 minute scanning period.  Little uptake was observed in the bladder and rectum.  </pharmacodynamics>
  <mechanism-of-action>Choline C 11 Injection is a radiolabeled analog of choline, a precursor molecule essential for the biosynthesis of cell membrane phospholipids.  Choline is involved in synthesis of the structural components of cell membranes, as well as modulation of trans-membrane signaling.  Increased phospholipid synthesis (i.e., increased uptake of choline) has been associated with cell proliferation and the transformation process that occurs in tumor cells. </mechanism-of-action>
  <toxicity/>
  <metabolism> Following intravenous administration, 11C-choline undergoes metabolism resulting  in the detection of 11C- betaine as the major metabolite in blood. In a study of patients with prostate cancer or brain disorders, the fractional activities of 11C-choline and 11C- betaine in human arterial plasma appeared to reach a plateau within 25 minutes, with 11C- betaine representing 82% Â± 9% of the total 11C detected at that time point.  A small amount of unmetabolized 11C-choline was detected within the blood at the final sampling time point (40 minutes). </metabolism>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination>Urinary excretion of 11C-choline was &lt; 2% of the  injected radioactivity at 1.5 hours after injection of the drug.</route-of-elimination>
  <volume-of-distribution>11C-choline distributes mainly to the pancreas, kidneys, liver, spleen and colon </volume-of-distribution>
  <clearance> The rate of 11C- choline excretion in urine was 0.014 mL/min. </clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as cholines. These are organic compounds containing a N,N,N-trimethylethanolammonium cation.</description>
    <direct-parent>Cholines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic nitrogen compounds</superclass>
    <class>Organonitrogen compounds</class>
    <subclass>Quaternary ammonium salts</subclass>
    <alternative-parent>1,2-aminoalcohols</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic cations</alternative-parent>
    <alternative-parent>Organic salts</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Tetraalkylammonium salts</alternative-parent>
    <substituent>1,2-aminoalcohol</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Alkanolamine</substituent>
    <substituent>Amine</substituent>
    <substituent>Choline</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic cation</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic salt</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Tetraalkylammonium salt</substituent>
  </classification>
  <salts/>
  <synonyms/>
  <products>
    <product>
      <name>Choline C 11</name>
      <labeller>Mayo Clinic</labeller>
      <ndc-id/>
      <ndc-product-code>52670-566</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-12</started-marketing-on>
      <ended-marketing-on>2014-11-13</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>33.1 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA203155</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Choline C 11</name>
      <labeller>Ucsf Radiopharmaceutical Facility</labeller>
      <ndc-id/>
      <ndc-product-code>24275-0485</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>33.1 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA208444</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Choline C 11</name>
      <labeller>University Of Texas Md Anderson Cancer Center</labeller>
      <ndc-id/>
      <ndc-product-code>60215-111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>100 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA205690</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Choline C 11</name>
      <labeller>Global Isotopes, Llc D/B/A Zevacor Molecular</labeller>
      <ndc-id/>
      <ndc-product-code>69126-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA206319</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Choline C 11</name>
      <labeller>Decatur Memorial Hospital</labeller>
      <ndc-id/>
      <ndc-product-code>73410-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>4 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA206319</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Choline C 11</name>
      <labeller>Mayo Clinic</labeller>
      <ndc-id/>
      <ndc-product-code>52670-556</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>33.1 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA203155</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Choline C 11</name>
      <labeller>University Of Texas Md Anderson Cancer Center</labeller>
      <ndc-id/>
      <ndc-product-code>60215-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-29</started-marketing-on>
      <ended-marketing-on>2018-10-31</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>33.1 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA205690</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Choline C 11</name>
      <labeller>Precision Nuclear Llc</labeller>
      <ndc-id/>
      <ndc-product-code>52768-300</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-06-07</started-marketing-on>
      <ended-marketing-on>2014-06-07</ended-marketing-on>
      <dosage-form>Injection</dosage-form>
      <strength>33.1 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Choline C 11</name>
      <labeller>Washington University School Of Medicine</labeller>
      <ndc-id/>
      <ndc-product-code>75913-311</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-01-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength>33.1 mCi/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>ANDA208413</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mic B12</name>
      <labeller>Perdido Key Health And Wellness Inc</labeller>
      <ndc-id/>
      <ndc-product-code>70104-806</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection</dosage-form>
      <strength/>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Choline C 11</name>
      <ingredients>Choline C-11</ingredients>
    </mixture>
    <mixture>
      <name>Mic B12</name>
      <ingredients>Choline C-11 + Inositol + Methionine sulfoximine + Methylcobalamin</ingredients>
    </mixture>
    <mixture>
      <name>Choline C 11</name>
      <ingredients>Choline C-11</ingredients>
    </mixture>
    <mixture>
      <name>Choline C 11</name>
      <ingredients>Choline C-11</ingredients>
    </mixture>
    <mixture>
      <name>Choline C 11</name>
      <ingredients>Choline C-11</ingredients>
    </mixture>
    <mixture>
      <name>Choline C 11</name>
      <ingredients>Choline C-11</ingredients>
    </mixture>
    <mixture>
      <name>Choline C 11</name>
      <ingredients>Choline C-11</ingredients>
    </mixture>
    <mixture>
      <name>Choline C 11</name>
      <ingredients>Choline C-11</ingredients>
    </mixture>
    <mixture>
      <name>Choline C 11</name>
      <ingredients>Choline C-11</ingredients>
    </mixture>
    <mixture>
      <name>Choline C 11</name>
      <ingredients>Choline C-11</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Radioactive Diagnostic Agent</category>
      <mesh-id/>
    </category>
    <category>
      <category>Radiopharmaceutical Activity</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>100 mCi/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>33.1 mCi/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intravenous</route>
      <strength>4 mCi/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Intramuscular</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-3.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.61e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-4.7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(2-hydroxyethyl)((11C)methyl)dimethylazanium</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>(2-hydroxyethyl)((11C)methyl)dimethylazanium</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>103.173</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>103.118424313</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>C[N+](C)([11CH3])CCO</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C5H14NO</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C5H14NO/c1-6(2,3)4-5-7/h7H,4-5H2,1-3H3/q+1/i1-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>OEYIOHPDSNJKLS-BJUDXGSMSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>20.23</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>42.19</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>12.57</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>13.97</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>72322</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>449688</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827881</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>396147</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>